Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients

Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B-cell lymphoma or acute lymphoblastic leukemia. Impaired T-cell fitness of CLL patients may b...

Full description

Bibliographic Details

Main Authors:	Fan, Fuli (Author) , Yoo, Hyeon Joo (Author) , Stock, Sophia (Author) , Wang, Lei (Author) , Liu, Yibin (Author) , Schubert, Maria-Luisa (Author) , Wang, Sanmei (Author) , Neuber, Brigitte (Author) , Hückelhoven-Krauss, Angela (Author) , Gern, Ulrike (Author) , Schmitt, Anita (Author) , Müller-Tidow, Carsten (Author) , Dreger, Peter (Author) , Schmitt, Michael (Author) , Sellner, Leopold (Author)
Format:	Article (Journal)
Language:	English
Published:	2021
In:	International journal of cancer Year: 2021, Volume: 148, Issue: 2, Pages: 419-428
ISSN:	1097-0215
DOI:	10.1002/ijc.33212
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.33212 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33212
Author Notes:	Fuli Fan, Hyeon Joo Yoo, Sophia Stock, Lei Wang, Yibin Liu, Maria-Luisa Schubert, Sanmei Wang, Brigitte Neuber, Angela Hückelhoven-Krauss, Ulrike Gern, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Leopold Sellner